JGL has become an authorised distributor of oral drug formulations for the Medochemie pharmaceutical company. Partnership with one of the largest European manufacturers of generic drugs will greatly contribute to JGL’s efforts to further expand its prescription medicines portfolio in order to meet client needs more quickly and efficiently.
A large number of products have already been registered with the Croatian Agency for Medicinal Products and Medical Devices (HALMED) and included in the Croatian Health Institute (CIHI) list. JGL has begun distributing medications from different therapy groups, making the following preparations available on the market:
- Oral antidiabetic drug combinations: vildagliptin/metformin, under the brand name Daltex
- Penicillin and beta-lactamase inhibitor combinations: amoxicillin/clavulanic acid, under the brand name Medoclav
- Other antiepileptic drugs: pregabalin, under the brand name Siranalen
- Other antipsychotics: aripiprazole, under the brand name Zykalor
Medochemie is a well-established company from Cyprus that operates in over a hundred markets worldwide. The company has a portfolio of over 630 different pharmaceutical products categorised in more than ten therapeutic groups, and operates 13 manufacturing facilities, 12 of which are headquartered in the European Union. As of this year, it also produces innovative drugs for the US pharmaceutical giant Pfizer.
New product launches are planned for the second half of 2019, and cooperation between JGL and Medochemie will continue in the coming years.